Novel therapeutic agents in Waldenström's macroglobulinemia.

Irene M. Ghobrial,Xavier Leleu,Abdel Kareem Azab,Judith Runnels,Xiaoying Jia,Hai Ngo,Molly Melhem,Feda Azab,Antonio Sacco,Phong Quang,Nicholas Burwick,Anne-Sophie Moreau,Emanuel Husu,Mena Farag,Aldo Roccaro

Clinical Lymphoma and Myeloma（2009）

引用 4|浏览5

暂无评分

摘要

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.

查看译文

关键词

Akt,Bortezomib,Everolimus,Perifosine,Waldenström

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要